CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Vein360

Vein 360 Specializes in reprocessing Closurefast Ablation Catheters. The Vein 360 team is dedicated to providing cost effective reprocessing services.

Gensource-Rx

Gensource-Rx is a Carlstadt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

growve

Growve is a company that specializes in acquiring, operating, and growing world class brands in the supplements & active nutrition, beauty & personal care, home & leisure, lifestyle foods, and pet care verticals.

Viatris

VIATRIS™ is a new kind of global healthcare company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of approximately ~45,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance.

Medac Corporation

Medac Corporation is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.